Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors

INTRODUCTION: AZD4877 is a potent Eg5 inhibitor that has been shown to have an acceptable tolerability profile in a Phase I study of Western patients with solid tumors. This study was conducted to evaluate the safety, pharmacokinetic (PK) profile, maximum tolerated dose (MTD) and efficacy of AZD4877...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Esaki, Taito, Seto, Takashi, Ariyama, Hiroshi, Arita, Shuji, Fujimoto, Chinatsu, Tsukasa, Koichiro, Kometani, Takuro, Nosaki, Kaname, Hirai, Fumihiko, Yagawa, Katsuro
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Inc 2011
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3130141/
https://ncbi.nlm.nih.gov/pubmed/21765863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1753-5174.2011.00034.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados